William L. Mentlik

Aaron S. Eckenthal

Tedd W. van Buskirk

Andrew S. Chalson

F. Dominic Cerrito

Evangeline Shih

William C. Baton

Charles M. Lizza

Sarah Ann Sullivan

Gabriel P. Brier

Eric C. Stops

Steven J. Corr

Matthew J. Hertko

David L. Moses

Marta Godecki

Brian J. Forsatz

Frank C. Calvosa

Cary Miller

ANDA filing triggers Celgene suit to block generic REVLIMID®, accusing infringers over patents on the drug's specific 'unsolvated crystalline Form A'.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Name	Ratings
Quinn Emanuel Urquhart & Sullivan LLP	L5 A
F. Dominic Cerrito	L5 A
Eric C. Stops	L4 C
Evangeline Shih	L3 B
Andrew S. Chalson	L2 B
Frank C. Calvosa	L2 B
Gabriel P. Brier	L2 C
Brian J. Forsatz	L2 C
Marta Godecki	L1 C
Jones Day	L5 A
Steven J. Corr	L3 B
Matthew J. Hertko	L3 C
Cary Miller	L1 B
Saul Ewing LLP	L3 B
William C. Baton	L5 A
Charles M. Lizza	L5 A
Sarah Ann Sullivan	L5 A
David L. Moses	L2 B

Name	Ratings
Lotus Pharmaceutical Co Ltd	-- -- --
Alvogen Pine Brook LLC	L1 C

Name	Ratings
Lerner David Littenberg Krumholz & Mentlik LLP	L3 E
William L. Mentlik	L5 E
Tedd W. van Buskirk	L2 E
Aaron S. Eckenthal	L1 E

2:18-cv-11518

Celgene Corp v. Lotus Pharmaceutical Co Ltd